Structure Therapeutics Inc. American Depositary Shares (GPCR · NASDAQ)

Structure Therapeutics (GPCR) fell to a 52-week low of $25.56, down 33.9% over the past month and 44.5% over three months, leaving shares 72.8% below their 52-week high. The clinical-stage biopharmaceutical company, which has no revenue, posted a Q2 net loss of $106.2M on operating expenses of $118.6M, widening from a $76.2M net loss in Q1, and missed EPS estimates in three of its last four quarters. The balance sheet remains liquid, with $272.6M in cash, minimal debt of $6.2M, and a current ratio of 20.75, against a market cap of $1.82B. The analyst target stands at $105.78, though the stock's RSI of 1 and trading at 0.4x average volume underscore deeply oversold conditions.